Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Myriad Genetics Inc News

    18,035 $ -3,19% -0,595 $
    In : 16,800 € | 19:17:03 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 897518
    ISIN: US62855J1043
    US-Symbol: MYGN
    Typ: Aktie

    Unternehmensmeldungen

    31.08.22 - GlobeNewswire
    New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
    Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy SALT LAKE CITY, Aug. ...
    31.08.22 - GlobeNewswire
    Neue Studie, im Clinical Cancer Research Journal veröffentlicht, unterstreicht die Bedeutung des EndoPredict-Tests zur Information über die Behandlung von prämenopausalen Brustkrebs-Patientinnen
    Myriad Genetics’ EndoPredict-​Test identifiziert präzise prämenopausale Frauen mit ER+, HER2-Brustkrebs, die eine adjuvante Chemotherapie vermeiden können SALT LAKE CITY, ...
    16.08.22 - GlobeNewswire
    Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe
    Collaboration brings MyChoice CDx Plus Testing to Hamburg, Germany and Dijon, France Latest expansions represent Myriad’s commitment to growing international lab partner ...
    16.08.22 - GlobeNewswire
    Myriad Genetics kooperiert mit dem Institut für Hämopathologie Hamburg und dem Centre Georges-Francois LeClerc, um den Zugang zu Gentests in Europa zu erweitern
    Zusammenarbeit bringt MyChoice CDx Plus Tests nach Hamburg, Deutschland und Dijon, Frankreich Jüngste Erweiterungen zeigen untermauern Myriad’s Verpflichtung gegenüber ...
    19.10.20 - GlobeNewswire
    Gemeinsamer Bundesausschuss (G-BA) fasst Beschluss zur Erstattung der Kosten des Brustkrebs-Prognosetests EndoPredict® durch die gesetzlichen Krankenkassen
    NICHT ZUR VERTEILUNG AN NACHRICHTENAGENTUREN DER VEREINIGTEN STAATEN ODER ZUR VERBREITUNG IN DEN VEREINIGTEN STAATEN
    16.10.20 - GlobeNewswire
    German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test
    /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
    08.10.16 - GlobeNewswire
    Myriad's myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib
    Myriad's myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) --  ...
    11.07.16 - GlobeNewswire
    Myriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of the National Cancer Institute
    Myriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of the National Cancer Institute "EPclin (EndoPredict) Markedly Outperformed RS ...
    31.05.16 - GlobeNewswire
    Myriad Acquires Sividon Diagnostics
    Myriad Acquires Sividon Diagnostics Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict® SALT LAKE CITY, May 31, 2016 ...
    01.10.15 - GlobeNewswire
    Myriad Appoints Jan Schluchter as Chief Commercial Officer for Europe
    Myriad Appoints Jan Schluchter as Chief Commercial Officer for Europe Former Executive at Novartis Joins Myriad's International Leadership Team SALT LAKE CITY and ZURICH, ...
    24.09.15 - GlobeNewswire
    Myriad Genetics Presents New Data on Its Companion Diagnostic and Prostate Cancer Tests at the European Society for Medical Oncology Annual Meeting
    Myriad Genetics Presents New Data on Its Companion Diagnostic and Prostate Cancer Tests at the European Society for Medical Oncology Annual Meeting SALT LAKE CITY, Sept. ...
    08.01.15 - GlobeNewswire
    Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors
    Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors Identifies Up to 44 Percent More Eligible ...
    24.10.14 - GlobeNewswire
    Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe
    Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe Tumor BRACAnalysis CDx Will Identify More Patients for Treatment With PARP Inhibitors SALT LAKE CITY ...
    14.05.14 - DGAP
    Crescendo Bioscience's Vectra(R) DA Predicts Radiographic Progression in Patients With Early Rheumatoid Arthritis
    DGAP-News: Myriad Genetics, Inc. / Crescendo Bioscience's Vectra(R) DA Predicts Radiographic Progression in Patients With Early Rheumatoid Arthritis 14.05.2014 / 13:05 --------------...
    07.04.14 - DGAP
    Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)
    DGAP-News: Myriad Genetics, Inc. / Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R) 07.04.2014 / 22:30 --------------------------------------------------------------------- B...
    07.04.14 - DGAP
    /K I L L K I L L K I L L -- Myriad Genetics, Inc.
    DGAP-News: Myriad Genetics, Inc. / /K I L L K I L L K I L L -- Myriad Genetics, Inc. 07.04.2014 / 16:53 --------------------------------------------------------------------- SALT LAKE CITY, 2014-04-07 ...
    07.04.14 - DGAP
    Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)
    DGAP-News: Myriad Genetics, Inc. / Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R) 07.04.2014 / 08:15 --------------------------------------------------------------------- B...
    20.03.14 - DGAP
    Institut Pasteur and Myriad RBM Publish Initial Results From Landmark Study of Immune Response
    DGAP-News: Myriad Genetics, Inc. / Institut Pasteur and Myriad RBM Publish Initial Results From Landmark Study of Immune Response 20.03.2014 / 21:00 -------------------------------------...
    20.01.14 - DGAP
    Myriad Genetics and Sividon Diagnostics Announce Exclusive Co-Marketing Agreement for EndoPredict(R) Outside of the United States
    DGAP-News: Myriad Genetics, Inc. / Myriad Genetics and Sividon Diagnostics Announce Exclusive Co-​Marketing Agreement for EndoPredict(R) Outside of the United States 20.01.2014...

    Newssuche

    Videos

    newspaper
    09:30 Uhr +34,15%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »